Safety of B-blockers in Patients with Chronic Hepatitis C under Treatment with sofosbuvir and Daclatasvir

Abstract

Corresponding author: Muhammad Nasser Muhammad Ajlan, Resident of Internal Medicine, Aswan University Hospital, Aswan, Egypt e-mail: mnassermajlan@gmail.c om 010 133 17972 Abstract: Background: It’s known that hepatitis C virus (HCV) one of the major health problems worldwide. Direct acting analogues (DAAs) are tolerable effective and safe agents for therapy of HCV. Till now, there are confirmed documentations about cardiovascular effects of DAAs. Aim of the work: this work was designed to determine safety of B-blockers use in chronic HCV patients under treatment with sofosbuvir. Methodology: A case control study was carried out on 60 patients with chronic HCV not hypertensive (control group) and 60 patients with chronic HCV and hypertensive on beta blockers therapy (study group). All patients were subjected to evaluation with electrocardiography at baseline before therapy and each month for three months of therapy. Results: There was no statistically significant difference between the studied groups as regard heart block. Only one patient in control group and 8 patients in study group developed heart block. Conclusion: Patients with underlying cardiovascular disease should be closely monitored if they receive sofosbuvir for HCV infection.